Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor

PDGFRA公司 主旨 外显子 医学 突变 胃肠病学 内科学 间质瘤 肿瘤科 病理 癌症研究 间质细胞 生物 基因 遗传学
作者
Wen Huang,Wei Yuan,Lei Ren,Huaiyu Liang,Xiangyang Du,Xiangfei Sun,Yong Fang,Xiao‐Dong Gao,Min Fu,Yihong Sun,Kuntang Shen,Yingyong Hou
出处
期刊:Pathology Research and Practice [Elsevier BV]
卷期号:239: 154138-154138 被引量:6
标识
DOI:10.1016/j.prp.2022.154138
摘要

Platelet-Derived Growth Factor Receptor Alpha (PDGFRA) mutation has causes a rare subgroup of gastrointestinal stromal tumor (GIST) and not too much attention has been paid on it until the appearance of Avapritinib. This study aims to explore the clinicopathological features, therapy and prognosis of PDGFRA-mutant GIST for better understanding and clinical practice.119 PDGFRA-mutant GIST patients were retrospectively collected from 2038 patients who underwent genetic testing. Kaplan-Meier method was used.The incidence rate of PDGFRA-mutant GIST in our center was 5.8 %, with 79 males, 40 females, and a median age of 57 (25⁃80) years old. All the tumors were in the stomach, among which 60 were epithelioid type, 25 were spindle type and 34 were mixed type. There were 13 cases of exon 12 mutation and 106 cases of exon 18 mutation including 83 cases of D842V mutation (69.7 %). During a median follow⁃up of 49.6 (range, 1⁃154) months, progression could be observed in 12 patients with gene mutation at the codon 842 of exon 18, another case was V561D mutation in exon 12. The 5-year diseases⁃free survival (DFS) was 90.1 %, which was associated with the loss of CD34 expression (P<0.001). Patients in D842V group showed a marginal worse prognosis than those in non-D842V group (P = 0.163). According to the NIH criteria, high risk group showed a poorer prognosis than non-high risk group (P = 0.003), however, there were no significant differences among the three non-high risk groups (P = 0.495, P = 0.652). Among 13 advanced patients, 5 cases (treated with Avapritinib) achieved partial remission.PDGFRA-mutant GIST mostly derived from stomach, with a relative indolent behavior. D842V mutation and lose of CD34 expression were adverse prognostic factors. Avapritinib can effectively control advanced patients in a certain period of time.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lqx完成签到,获得积分10
1秒前
百里完成签到 ,获得积分20
2秒前
2秒前
无辜飞风完成签到,获得积分10
3秒前
负责以山完成签到 ,获得积分10
5秒前
科研通AI2S的应助被风吹麦浪采纳,获得10
5秒前
王培德发布了新的文献求助10
5秒前
英姑的应助被风吹麦浪采纳,获得10
5秒前
科研通AI6.2的应助被风吹麦浪采纳,获得10
5秒前
Husile发布了新的文献求助10
7秒前
刻苦的媚颜完成签到 ,获得积分10
8秒前
10秒前
10秒前
xxy发布了新的文献求助10
10秒前
11秒前
Keep完成签到,获得积分10
11秒前
hehe完成签到,获得积分10
11秒前
vnewgnl的应助被drizzle采纳,获得10
12秒前
HJJHJH发布了新的文献求助10
15秒前
Nole的应助被苦瓜采纳,获得10
16秒前
上官若男的应助被阔达的冰露采纳,获得10
16秒前
17秒前
桐桐的应助被Vater采纳,获得10
18秒前
可爱的函函的应助被HJJHJH采纳,获得10
19秒前
19秒前
dxw完成签到,获得积分10
19秒前
20秒前
77完成签到,获得积分10
22秒前
眼睛大的小熊猫完成签到,获得积分10
22秒前
清爽难破完成签到 ,获得积分10
24秒前
24秒前
NingCp完成签到,获得积分10
25秒前
25秒前
26秒前
26秒前
26秒前
传奇3的应助被quantu采纳,获得10
26秒前
踏实以松发布了新的文献求助10
26秒前
丘比特的应助被幽凡采纳,获得10
28秒前
林林完成签到 ,获得积分10
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186734
求助须知:如何正确求助?哪些是违规求助? 9575007
关于积分的说明 21839114
捐赠科研通 7784289
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559206
邀请新用户注册赠送积分活动 2481611